Genetic Markers Predict Primary Nonresponse and Durable Response to Anti–Tumor Necrosis Factor Therapy in Ulcerative Colitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Genetic Markers Predict Primary Nonresponse and Durable Response to Anti–Tumor Necrosis Factor Therapy in Ulcerative Colitis

Published:2018-04-30 Issue:8 Volume:24 Page:1840-1848
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Burke Kristin E¹²,Khalili Hamed¹²,Garber John J¹²,Haritunians Talin³,McGovern Dermot P B³,Xavier Ramnik J¹²,Ananthakrishnan Ashwin N¹²

Affiliation:

1. Inflammatory Bowel Disease Center, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts

2. Harvard Medical School, Boston, Massachusetts

3. F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California

Funder

American Gastroenterological Association

Leona M. and Harry B. Helmsley Charitable Trust

Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute

U.S. Public Health Service

National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/8/1840/26499528/izy083.pdf

Reference40 articles.

1. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus;Bressler;Gastroenterology,2015

2. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management;Dignass;J Crohns Colitis,2012

3. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response;D’Haens;Am J Gastroenterol,2011

4. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization;Oussalah;Am J Gastroenterol,2010

5. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab;Papamichael;J Crohns Colitis,2016

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study;Gastroenterología y Hepatología (English Edition);2024-08

2. HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2024-06-27

3. The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2024-05-26

4. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study;Gastroenterología y Hepatología;2023-12

5. Precision medicine in inflammatory bowel disease;Precision Clinical Medicine;2023-10-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3